Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 9/20 | 0.49 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.45 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | HRH1 | P35367 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | DRD5 | P21918 | 1/20 | 0.39 |
| ▸ | HRH2 | P25021 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14299747 | 0.96 | CYP19A1 (0.46) | CYP19A1SCN5ACACNA1BSLC6A3HTR2A | |
| SCHEMBL904927 | 0.80 | CYP19A1 (0.47) | CYP19A1SCN5ACACNA1BSLC6A3MAPK1 | |
| SCHEMBL8678280 | 0.80 | CYP19A1 (0.47) | CYP19A1SCN5ACACNA1BSLC6A3HTR2A | |
| SCHEMBL2862310 | 0.80 | HRH1 (0.65) | CYP19A1SCN5ACACNA1BSLC6A3HTR2A | |
| SCHEMBL6264296 | 0.80 | CYP19A1 (0.47) | CYP19A1SCN5ACACNA1BSLC6A3HTR2A | |
| SCHEMBL5864161 | 0.80 | CYP19A1 (0.47) | CYP19A1SCN5ACACNA1BSLC6A3HTR2A | |
| SCHEMBL318816 | 0.80 | CYP19A1 (0.47) | CYP19A1SCN5ACACNA1BSLC6A3HTR2A | |
| Hydrochloric Acid SCHEMBL7389223 | 0.78 | HRH1 (0.63) | CYP19A1SCN5ACACNA1BSLC6A3HTR2A | |
| SCHEMBL22028771 | 0.78 | HRH1 (0.57) | CYP19A1SCN5ACACNA1BSLC6A3HTR2A | |
| SCHEMBL7331536 | 0.78 | CYP19A1 (0.46) | CYP19A1SCN5ACACNA1BSLC6A3TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018011375-A1 | MECLOZINE DERIVATIVES AND DICLAZURIL DERIVATIVES FOR USE IN THE PREVENTION AND/OR THE TREATMENT OF DISORDERS ASSOCIATED TO THE INFLAMMATION INDUCED BY P. ACNES | UNIVERSITE PARIS DESCARTES (FR) | 2018-01-18 | — | — | WO | disclosed |
| US-8354434-B2 | Cyclourea compounds as calcium channel blockers | PURDUE PHARMA L.P. (US) | 2013-01-15 | — | — | US | disclosed |
| US-8354434-B2 | Cyclourea compounds as calcium channel blockers | PURDUE PHARMA L.P. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120322830-A1 | Cyclourea Compounds as Calcium Channel Blockers | PURDUE PHARMA L.P. (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120322830-A1 | Cyclourea Compounds as Calcium Channel Blockers | PURDUE PHARMA L.P. (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120309778-A1 | Fused and Spirocycle Compounds and the Use Thereof | PURDUE PHARMA L.P. (US) | 2012-12-06 | — | — | US | disclosed |
| US-20090176838-A1 | Cyclourea Compounds as Calcium Channel Blockers | PURDUE PHARMA L.P. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090176838-A1 | Cyclourea Compounds as Calcium Channel Blockers | PURDUE PHARMA L.P. (US) | 2009-07-09 | — | — | US | disclosed |
| WO-2007085357-A1 | CYCLOUREA COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | EURO-CELTIQUE S.A. (LU) | 2007-08-02 | — | — | WO | disclosed |
| US-20040006081-A1 | Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2004-01-08 | — | — | US | disclosed |
| EP-1289957-A1 | PHARMACEUTICALLY ACTIVE PIPERIDINE DERIVATIVES, IN PARTICULAR AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2003-03-12 | — | — | EP | disclosed |
| US-6403589-B1 | NUCLEOSIDE TRANSPORT INHIBITOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-06-11 | — | — | US | disclosed |
| WO-2001087839-A1 | PHARMACEUTICALLY ACTIVE PIPERIDINE DERIVATIVES, IN PARTICULAR AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2001-11-22 | — | — | WO | disclosed |
| EP-0999840-A1 | USE OF DRAFLAZINE-ANALOGUES FOR TREATING PAIN | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-05-17 | — | — | EP | disclosed |
| WO-1998057643-A1 | USE OF DRAFLAZINE-ANALOGUES FOR TREATING PAIN | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-12-23 | — | — | WO | disclosed |
| US-4766125-A | N-aryl-piperazinealkanamides useful for protecting hearts from myocardial injury caused by ischaemia, anoxia or hypoxia | JANSSEN PHARMACEUTICA N.V. (BE) | 1988-08-23 | — | — | US | disclosed |
| EP-0068544-B1 | NOVEL N-ARYL-PIPERAZINEALKANAMIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1987-06-03 | — | — | EP | disclosed |
| US-4410536-A | 7,8,9,10-Tetrahydrothieno[3,2-e]pyrido[4,3-b]indole compounds and their anti-depressant use | TROPONWERKE GMBH & CO. K.G. (DE) | 1983-10-18 | — | — | US | disclosed |
| EP-0068544-A2 | Novel N-aryl-piperazinealkanamides | JANSSEN PHARMACEUTICA N.V. (BE) | 1983-01-05 | — | — | EP | disclosed |
| US-3989707-A | NEUROLEPTIC AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1976-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322830-A1 | Cyclourea Compounds as Calcium Channel Blockers | CACNA1E, CACNA1B, CACNA1D | CYP19A1 4534/4885SCN5A 135/4885CACNA1B 2/4885 |
| US-20090176838-A1 | Cyclourea Compounds as Calcium Channel Blockers | CACNA1E, CACNA1B, CACNA1D | CYP19A1 4534/4885SCN5A 135/4885CACNA1B 2/4885 |
| US-20040006081-A1 | Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity | CCR5, CCR2, CCR1 | CYP19A1 2675/4885SCN5A 1579/4885CACNA1B 2141/4885 |
| US-20120309778-A1 | Fused and Spirocycle Compounds and the Use Thereof | CACNA1A, CACNA1E, CACNA1C | CYP19A1 909/4885SCN5A 33/4885CACNA1B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.